[go: up one dir, main page]

WO2004095942A2 - Comprime contenant de la cafeine - Google Patents

Comprime contenant de la cafeine Download PDF

Info

Publication number
WO2004095942A2
WO2004095942A2 PCT/DE2004/000843 DE2004000843W WO2004095942A2 WO 2004095942 A2 WO2004095942 A2 WO 2004095942A2 DE 2004000843 W DE2004000843 W DE 2004000843W WO 2004095942 A2 WO2004095942 A2 WO 2004095942A2
Authority
WO
WIPO (PCT)
Prior art keywords
mass
tablet according
caffeine
tablet
isomalt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2004/000843
Other languages
German (de)
English (en)
Other versions
WO2004095942A3 (fr
Inventor
Klaus Eichler
Wolfgang Kempe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipc Prozess Center & Co GmbH
Original Assignee
Ipc Prozess Center & Co GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10339864A external-priority patent/DE10339864A1/de
Application filed by Ipc Prozess Center & Co GmbH filed Critical Ipc Prozess Center & Co GmbH
Publication of WO2004095942A2 publication Critical patent/WO2004095942A2/fr
Publication of WO2004095942A3 publication Critical patent/WO2004095942A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A23L2/395—Dry compositions in a particular shape or form
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/40—Effervescence-generating compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Definitions

  • the invention relates to a caffeine-containing tablet with which caffeine is made available for oral ingestion.
  • caffeine is usually taken in the form of cold and hot drinks, possibly with the addition of other substances that influence the taste of the drinks.
  • the caffeine-containing tablets according to the invention are composed in such a way that, in addition to the powdered caffeine, isomalt and xylitol, which form the largest proportion of the composition (a minimum mass fraction of 50%), additionally an aroma substance or an aroma substance mixture and with a low one Share a binder are included.
  • Such a tablet should not contain more than a total of 150 mg, preferably not more than 100 mg, particularly preferably 50 mg of caffeine.
  • At least 20% by mass, preferably approximately 50% by mass, of the powdered caffeine should be enclosed with such a protective cover.
  • This effect can be spread out over time if individual powder particles are coated with caffeine with protective casings of different thicknesses or if different substances are used to form protective casings, which can preferably be solved differently in the digestive tract.
  • Caffeine can also be influenced in such a way that it only occurs in the digestive tract. This can also be achieved with different protective covers, stretched in time and differentiated in time in the digestive tract, so that an extended total active time can be achieved. Stearic acid has proven to be preferred for the formation of such protective shells on caffeine powder particles.
  • a cellulose derivative or shellac can also be used to form the protective cover.
  • the protective covers can also be formed from a natural wax, preferably carnauba wax.
  • the substances already mentioned as constituents of tablets according to the invention namely isomalt and xylitol, not only essentially form the carrier matrix of such tablets, but also ensure a pleasant, sweet taste, even though no sugar is used.
  • Xylitol also has a beneficial plaque removal effect.
  • Tablets consisting of at least 60% by mass up to 90% by mass of isomalt and xylotol can simply be swallowed, sucked in the mouth or chewed.
  • Tablets containing sodium bicarbonate should also contain citric acid in addition to the flavorings already mentioned to improve the taste and release of gases in order to achieve a refreshing taste improvement.
  • citric acid should shot to achieve a sufficient release of carbon dioxide.
  • the soluble effervescent tablets containing sodium bicarbonate show a comparison to beverages
  • Such effervescent tablets should preferably be enclosed individually, if appropriate several, together after manufacture for the transport and storage period by a gas-tight film. The inclusion is intended to ensure the smallest possible volume of air inside and prevent the ingress of moisture.
  • the tablets according to the invention can be produced in such a way that caffeine powder, isomalt and xylitol are mixed with one another and a suitable binder is added.
  • the binder comes, for example, as an inert binder, e.g. Hydroxypropylmethylcellulose in question, where the binder content can be about 1 to 10% by mass.
  • An encapsulated flavoring or a flavoring mixture can already be contained, but can also be added later.
  • This mixture is then granulated, which can be done in a fluidized bed system, but also in other suitable mixing devices.
  • the granules thus obtained are then dried until a residual moisture content of 1 to 5%, preferably up to 2%, % has been obtained.
  • the granulate prepared in this way can be screened off in order to ensure a relatively uniform grain size distribution.
  • a solid tablet for sucking or chewing can contain 20 to 35 mass% caffeine, in which a ratio of approx. 2 to 3 is advantageous for pure caffeine powder provided with a protective cover, 60 to 80 mass% isomalt and xylitol , 1.5 to 5% by mass of aroma or aroma mixture as well as hydroxypropylmethyl cellulose (approx. 3-5% by mass) and magnesium stearate (approx. 0.3 to 1% by mass) and possibly small proportions of a colorant.
  • the protective covers for caffeine should consist of carnauba wax.
  • Such a tablet can then contain 119 mg of isomalt, 116 mg of xylitol, 9 mg of flavoring, 39.7 mg of pure caffeine, 59.5 mg of caffeine coated with canauba wax, 4.4 mg of hydroxypropylmethyl cellulose, 2 mg of magnesium stearate and contain less than 1 mg of a dye.
  • a 2 g tablet can contain 1000 mg isomalt, 900 mg xylitol, 50 mg caffeine, 25 mg of which in pure form and 25 mg with a stearic acid coating, and 20 mg of flavoring.
  • a "effervescent tablet” that dissolves easily in water can have the same total mass of 2g, 700 mg isomalt, 700 mg xylitol, 250 mg sodium bicarbonate, 250 mg citric acid, 50 mg caffeine, which in turn can be partially surrounded by a protective cover and 20 mg of a flavoring.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des comprimés contenant de la caféine qui peuvent être appliqués oralement, qui présentent un goût amélioré et qui sont au moins pratiquement exempts d'effets nuisibles à la santé indésirables. Les comprimés contenant de la caféine selon l'invention contiennent, outre de la caféine en poudre, de l'isomalte et du xylitol à parts approximativement égales, qui forment la plus grande partie, un produit aromatique ou un mélange de produits aromatiques, ainsi qu'un liant.
PCT/DE2004/000843 2003-04-30 2004-04-16 Comprime contenant de la cafeine Ceased WO2004095942A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10320049.5 2003-04-30
DE10320049 2003-04-30
DE10339864.3 2003-08-26
DE10339864A DE10339864A1 (de) 2003-04-30 2003-08-26 Coffein enthaltende Tablette

Publications (2)

Publication Number Publication Date
WO2004095942A2 true WO2004095942A2 (fr) 2004-11-11
WO2004095942A3 WO2004095942A3 (fr) 2005-01-06

Family

ID=33420008

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2004/000843 Ceased WO2004095942A2 (fr) 2003-04-30 2004-04-16 Comprime contenant de la cafeine

Country Status (1)

Country Link
WO (1) WO2004095942A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065140A1 (fr) * 2004-12-17 2006-06-22 4Sight Innovation B.V. Procede de preparation de produits permettant d'enrichir une boisson a l'aide d'additifs
CN103564593A (zh) * 2012-08-02 2014-02-12 佳格食品股份有限公司 具加强提神效果的泡腾片

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19615418A1 (de) * 1996-04-22 1997-10-23 Merck Patent Gmbh Polyol-Zusammensetzung
US6426090B1 (en) * 1999-04-06 2002-07-30 Wm. Wrigley Jr. Company Over-coated product including tableted center and medicament
DE19943491B4 (de) * 1999-09-10 2010-04-01 Südzucker AG Mannheim/Ochsenfurt Verbesserte Komprimate
US6444241B1 (en) * 2000-08-30 2002-09-03 Wm. Wrigley Jr. Company Caffeine coated chewing gum product and process of making
GB0107954D0 (en) * 2001-03-29 2001-05-23 Nestle Sa Chewing gum-containing tablet

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065140A1 (fr) * 2004-12-17 2006-06-22 4Sight Innovation B.V. Procede de preparation de produits permettant d'enrichir une boisson a l'aide d'additifs
CN103564593A (zh) * 2012-08-02 2014-02-12 佳格食品股份有限公司 具加强提神效果的泡腾片
CN105412041A (zh) * 2012-08-02 2016-03-23 佳格食品股份有限公司 具加强提神效果的泡腾片

Also Published As

Publication number Publication date
WO2004095942A3 (fr) 2005-01-06

Similar Documents

Publication Publication Date Title
EP0068191B1 (fr) Formes orales du dipyridamole
EP0108898B1 (fr) Formes galéniques orales de mopidamol
DE69231965T2 (de) Pharmazeutische formulierungen
DE60208673T2 (de) Umhüllte pellets auf basis eines ace-hemmers
DE69110592T2 (de) Pharmazeutische Zubereitung mit verbessertem Geschmack, poröse Partikel enthaltend, und deren Herstellungsmethode.
EP0759296B1 (fr) Composition pharmaceutique de tramadol ou d'un sel de tramadol à délitement rapide
LU86887A1 (de) Multimineralstoffpraeparate mit retardwirkung
DE3126703A1 (de) Bromhexin-retardform und verfahren zu ihrer herstellung
EP0434088A1 (fr) Compositions pharmaceutiques contenant de la L-carnitine
DE69205158T2 (de) Essbare pharmazeutische zusammensetzungen zur behandlung von verdauungstraktschmerzen.
DE102010024866A1 (de) Formulierung zur Geschmacksmaskierung
DE4022944A1 (de) Sucralfat-kautablette
CH680569A5 (fr)
EP1056448A1 (fr) Combinaisons pharmaceutiques contenant du tramadol
DE69209764T2 (de) Geschmacksabdeckende Überzüge zur Herstellung pharmazeutischer Kautabletten
WO2006002836A1 (fr) Compositions effervescentes de somniferes
EP0468245B1 (fr) Comprimé et granulé contenant MESNA comme agent actif
DE60013466T2 (de) Im mund zerfallende zusammensetzung mit mirtazapin
DE2343218A1 (de) Zubereitungsformen von n-(2-furfuryl)4-chlor-5-sulfamoylanthranilsaeure und verfahren zu ihrer herstellung
DE69816124T2 (de) Pharmazeutische zusammensetzungen enthaltend zafirlukast
WO2004095942A2 (fr) Comprime contenant de la cafeine
DE3414743C2 (de) Speise- Kau-, Quell- und Ballaststoff(e) mit Appetitzügler
DE69423643T2 (de) Schäumende gelatinkapselfüllung
DE10339864A1 (de) Coffein enthaltende Tablette
EP3042648B1 (fr) Granules directs a agent actif retarde

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase